| Characteristics . | TTV Copies/mL (IQR) . | P Value . | |
|---|---|---|---|
| Variable Positivea . | Variable Negativea . | ||
| Recipient data | |||
| Recipient age >56 yearsb | 4.2 × 108 (1.8 × 107–2.9 × 109) | 3.2 × 107 (3.6 × 106–4.0 × 108) | .050 |
| Recipient female | 9.3 × 106 (1.8 × 106–3.4 × 108) | 3.4 × 108 (1.8 × 107–2.4 × 109) | .021 |
| Recipient BMI >26 kg/m2 b | 4.2 × 108 (3.4 × 106–1.7 × 109) | 6.8 × 107 (8.3 × 106–4.2 × 108) | .629 |
| Renal replacement therapy >2.6 yearsb, c | 5.2 × 107 (5.3 × 106–8.3 × 108) | 1.8 × 108 (3.3 × 106–2.7 × 109) | .589 |
| Diabetes mellitus | 1.7 × 107 (2.8 × 106–4.3 × 108) | 1.8 × 108 (5.0 × 106–1.5 × 109) | .243 |
| Major comorbidityd | 5.2 × 107 (4.0 × 106–1.5 × 109) | 1.4 × 108 (3.9 × 106–1.1 × 109) | .978 |
| CMV IgG positive | 2.9 × 107 (3.4 × 106–5.3 × 109) | 4.3 × 108 (1.8 × 108–2.9 × 109) | .003 |
| EBV IgG positive | 7.6 × 107 (4.1 × 106–1.4 × 109) | 3.8 × 108 (3.5 × 108–NA) | .415 |
| HBc antibody positive | 7.3 × 106 (3.6 × 106–1.4 × 108) | 2.6 × 108 (8.0 × 106–1.7 × 109) | .074 |
| HIV antibody/antigen positive | NA | NA | .366 |
| Donor data | |||
| Living donor | 9.9 × 107 (1.2 × 107–4.3 × 108) | 1.8 × 108 (4.1 × 106–1.4 × 109) | .884 |
| Donor after circulatory death | 1.7 × 108 (1.6 × 105–7.6 × 108) | 2.4 × 108 (7.3 × 106–1.8 × 109) | .203 |
| Donor age >56 yearsb | 4.2 × 108 (9.3 × 106–2.9 × 109) | 3.0 × 107 (3.8 × 106–4.2 × 108) | .014 |
| Donor female | 3.1 × 107 (3.9 × 106–1.6 × 109) | 2.2 × 108 (7.2 × 106–1.0 × 109) | .699 |
| Donor CMV IgG positive | 3.4 × 107 (3.8 × 106–2.1 × 109) | 4.2 × 108 (1.1 × 107–1.6 × 109) | .164 |
| Transplant data | |||
| Retransplantation | 1.0 × 107 (9.9 × 105–3.3 × 108) | 2.6 × 108 (9.3 × 106–1.7 × 109) | .041 |
| ABO incompatible transplantation | 1.0 × 106 (6.3 × 105–1.8 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .633 |
| Donor specific antibody | 2.5 × 107 (1.8 × 106–2.1 × 108) | 1.8 × 108 (5.3 × 106–1.4 × 109) | .238 |
| HLA A, B, DR mismatch >3b | 4.7 × 107 (2.8 × 106–1.3 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .486 |
| ATG induction | 1.9 × 107 (2.3 × 106–1.5 × 108) | 1.8 × 108 (5.2 × 106–1.5 × 109) | .193 |
| CMV prophylaxis | 4.0 × 108 (4.0 × 107–1.8 × 109) | 3.1 × 107 (3.7 × 106–1.2 × 109) | .067 |
| Characteristics . | TTV Copies/mL (IQR) . | P Value . | |
|---|---|---|---|
| Variable Positivea . | Variable Negativea . | ||
| Recipient data | |||
| Recipient age >56 yearsb | 4.2 × 108 (1.8 × 107–2.9 × 109) | 3.2 × 107 (3.6 × 106–4.0 × 108) | .050 |
| Recipient female | 9.3 × 106 (1.8 × 106–3.4 × 108) | 3.4 × 108 (1.8 × 107–2.4 × 109) | .021 |
| Recipient BMI >26 kg/m2 b | 4.2 × 108 (3.4 × 106–1.7 × 109) | 6.8 × 107 (8.3 × 106–4.2 × 108) | .629 |
| Renal replacement therapy >2.6 yearsb, c | 5.2 × 107 (5.3 × 106–8.3 × 108) | 1.8 × 108 (3.3 × 106–2.7 × 109) | .589 |
| Diabetes mellitus | 1.7 × 107 (2.8 × 106–4.3 × 108) | 1.8 × 108 (5.0 × 106–1.5 × 109) | .243 |
| Major comorbidityd | 5.2 × 107 (4.0 × 106–1.5 × 109) | 1.4 × 108 (3.9 × 106–1.1 × 109) | .978 |
| CMV IgG positive | 2.9 × 107 (3.4 × 106–5.3 × 109) | 4.3 × 108 (1.8 × 108–2.9 × 109) | .003 |
| EBV IgG positive | 7.6 × 107 (4.1 × 106–1.4 × 109) | 3.8 × 108 (3.5 × 108–NA) | .415 |
| HBc antibody positive | 7.3 × 106 (3.6 × 106–1.4 × 108) | 2.6 × 108 (8.0 × 106–1.7 × 109) | .074 |
| HIV antibody/antigen positive | NA | NA | .366 |
| Donor data | |||
| Living donor | 9.9 × 107 (1.2 × 107–4.3 × 108) | 1.8 × 108 (4.1 × 106–1.4 × 109) | .884 |
| Donor after circulatory death | 1.7 × 108 (1.6 × 105–7.6 × 108) | 2.4 × 108 (7.3 × 106–1.8 × 109) | .203 |
| Donor age >56 yearsb | 4.2 × 108 (9.3 × 106–2.9 × 109) | 3.0 × 107 (3.8 × 106–4.2 × 108) | .014 |
| Donor female | 3.1 × 107 (3.9 × 106–1.6 × 109) | 2.2 × 108 (7.2 × 106–1.0 × 109) | .699 |
| Donor CMV IgG positive | 3.4 × 107 (3.8 × 106–2.1 × 109) | 4.2 × 108 (1.1 × 107–1.6 × 109) | .164 |
| Transplant data | |||
| Retransplantation | 1.0 × 107 (9.9 × 105–3.3 × 108) | 2.6 × 108 (9.3 × 106–1.7 × 109) | .041 |
| ABO incompatible transplantation | 1.0 × 106 (6.3 × 105–1.8 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .633 |
| Donor specific antibody | 2.5 × 107 (1.8 × 106–2.1 × 108) | 1.8 × 108 (5.3 × 106–1.4 × 109) | .238 |
| HLA A, B, DR mismatch >3b | 4.7 × 107 (2.8 × 106–1.3 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .486 |
| ATG induction | 1.9 × 107 (2.3 × 106–1.5 × 108) | 1.8 × 108 (5.2 × 106–1.5 × 109) | .193 |
| CMV prophylaxis | 4.0 × 108 (4.0 × 107–1.8 × 109) | 3.1 × 107 (3.7 × 106–1.2 × 109) | .067 |
Mann-Whitney U test was used for comparing continuous data and group comparisons were made using the Χ2 test. Exact tests were used where applicable.
Abbreviations: ATG, antithymoglobulin; BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein Barr virus; HBc, hepatitis B-core antigen; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; IgG immunoglobulin G; IQR, inter quartile range; NA, not applicable; TTV, torque teno virus.
aTTV levels preceding the first documented event (infection or no infection) per patient were analyzed.
bCutoff defined by median.
cTime between the start of renal replacement therapy and transplantation.
dAny history of major cardiovascular, gastrointestinal, pulmonary, or malignant disease.
| Characteristics . | TTV Copies/mL (IQR) . | P Value . | |
|---|---|---|---|
| Variable Positivea . | Variable Negativea . | ||
| Recipient data | |||
| Recipient age >56 yearsb | 4.2 × 108 (1.8 × 107–2.9 × 109) | 3.2 × 107 (3.6 × 106–4.0 × 108) | .050 |
| Recipient female | 9.3 × 106 (1.8 × 106–3.4 × 108) | 3.4 × 108 (1.8 × 107–2.4 × 109) | .021 |
| Recipient BMI >26 kg/m2 b | 4.2 × 108 (3.4 × 106–1.7 × 109) | 6.8 × 107 (8.3 × 106–4.2 × 108) | .629 |
| Renal replacement therapy >2.6 yearsb, c | 5.2 × 107 (5.3 × 106–8.3 × 108) | 1.8 × 108 (3.3 × 106–2.7 × 109) | .589 |
| Diabetes mellitus | 1.7 × 107 (2.8 × 106–4.3 × 108) | 1.8 × 108 (5.0 × 106–1.5 × 109) | .243 |
| Major comorbidityd | 5.2 × 107 (4.0 × 106–1.5 × 109) | 1.4 × 108 (3.9 × 106–1.1 × 109) | .978 |
| CMV IgG positive | 2.9 × 107 (3.4 × 106–5.3 × 109) | 4.3 × 108 (1.8 × 108–2.9 × 109) | .003 |
| EBV IgG positive | 7.6 × 107 (4.1 × 106–1.4 × 109) | 3.8 × 108 (3.5 × 108–NA) | .415 |
| HBc antibody positive | 7.3 × 106 (3.6 × 106–1.4 × 108) | 2.6 × 108 (8.0 × 106–1.7 × 109) | .074 |
| HIV antibody/antigen positive | NA | NA | .366 |
| Donor data | |||
| Living donor | 9.9 × 107 (1.2 × 107–4.3 × 108) | 1.8 × 108 (4.1 × 106–1.4 × 109) | .884 |
| Donor after circulatory death | 1.7 × 108 (1.6 × 105–7.6 × 108) | 2.4 × 108 (7.3 × 106–1.8 × 109) | .203 |
| Donor age >56 yearsb | 4.2 × 108 (9.3 × 106–2.9 × 109) | 3.0 × 107 (3.8 × 106–4.2 × 108) | .014 |
| Donor female | 3.1 × 107 (3.9 × 106–1.6 × 109) | 2.2 × 108 (7.2 × 106–1.0 × 109) | .699 |
| Donor CMV IgG positive | 3.4 × 107 (3.8 × 106–2.1 × 109) | 4.2 × 108 (1.1 × 107–1.6 × 109) | .164 |
| Transplant data | |||
| Retransplantation | 1.0 × 107 (9.9 × 105–3.3 × 108) | 2.6 × 108 (9.3 × 106–1.7 × 109) | .041 |
| ABO incompatible transplantation | 1.0 × 106 (6.3 × 105–1.8 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .633 |
| Donor specific antibody | 2.5 × 107 (1.8 × 106–2.1 × 108) | 1.8 × 108 (5.3 × 106–1.4 × 109) | .238 |
| HLA A, B, DR mismatch >3b | 4.7 × 107 (2.8 × 106–1.3 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .486 |
| ATG induction | 1.9 × 107 (2.3 × 106–1.5 × 108) | 1.8 × 108 (5.2 × 106–1.5 × 109) | .193 |
| CMV prophylaxis | 4.0 × 108 (4.0 × 107–1.8 × 109) | 3.1 × 107 (3.7 × 106–1.2 × 109) | .067 |
| Characteristics . | TTV Copies/mL (IQR) . | P Value . | |
|---|---|---|---|
| Variable Positivea . | Variable Negativea . | ||
| Recipient data | |||
| Recipient age >56 yearsb | 4.2 × 108 (1.8 × 107–2.9 × 109) | 3.2 × 107 (3.6 × 106–4.0 × 108) | .050 |
| Recipient female | 9.3 × 106 (1.8 × 106–3.4 × 108) | 3.4 × 108 (1.8 × 107–2.4 × 109) | .021 |
| Recipient BMI >26 kg/m2 b | 4.2 × 108 (3.4 × 106–1.7 × 109) | 6.8 × 107 (8.3 × 106–4.2 × 108) | .629 |
| Renal replacement therapy >2.6 yearsb, c | 5.2 × 107 (5.3 × 106–8.3 × 108) | 1.8 × 108 (3.3 × 106–2.7 × 109) | .589 |
| Diabetes mellitus | 1.7 × 107 (2.8 × 106–4.3 × 108) | 1.8 × 108 (5.0 × 106–1.5 × 109) | .243 |
| Major comorbidityd | 5.2 × 107 (4.0 × 106–1.5 × 109) | 1.4 × 108 (3.9 × 106–1.1 × 109) | .978 |
| CMV IgG positive | 2.9 × 107 (3.4 × 106–5.3 × 109) | 4.3 × 108 (1.8 × 108–2.9 × 109) | .003 |
| EBV IgG positive | 7.6 × 107 (4.1 × 106–1.4 × 109) | 3.8 × 108 (3.5 × 108–NA) | .415 |
| HBc antibody positive | 7.3 × 106 (3.6 × 106–1.4 × 108) | 2.6 × 108 (8.0 × 106–1.7 × 109) | .074 |
| HIV antibody/antigen positive | NA | NA | .366 |
| Donor data | |||
| Living donor | 9.9 × 107 (1.2 × 107–4.3 × 108) | 1.8 × 108 (4.1 × 106–1.4 × 109) | .884 |
| Donor after circulatory death | 1.7 × 108 (1.6 × 105–7.6 × 108) | 2.4 × 108 (7.3 × 106–1.8 × 109) | .203 |
| Donor age >56 yearsb | 4.2 × 108 (9.3 × 106–2.9 × 109) | 3.0 × 107 (3.8 × 106–4.2 × 108) | .014 |
| Donor female | 3.1 × 107 (3.9 × 106–1.6 × 109) | 2.2 × 108 (7.2 × 106–1.0 × 109) | .699 |
| Donor CMV IgG positive | 3.4 × 107 (3.8 × 106–2.1 × 109) | 4.2 × 108 (1.1 × 107–1.6 × 109) | .164 |
| Transplant data | |||
| Retransplantation | 1.0 × 107 (9.9 × 105–3.3 × 108) | 2.6 × 108 (9.3 × 106–1.7 × 109) | .041 |
| ABO incompatible transplantation | 1.0 × 106 (6.3 × 105–1.8 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .633 |
| Donor specific antibody | 2.5 × 107 (1.8 × 106–2.1 × 108) | 1.8 × 108 (5.3 × 106–1.4 × 109) | .238 |
| HLA A, B, DR mismatch >3b | 4.7 × 107 (2.8 × 106–1.3 × 109) | 1.8 × 108 (7.3 × 106–1.3 × 109) | .486 |
| ATG induction | 1.9 × 107 (2.3 × 106–1.5 × 108) | 1.8 × 108 (5.2 × 106–1.5 × 109) | .193 |
| CMV prophylaxis | 4.0 × 108 (4.0 × 107–1.8 × 109) | 3.1 × 107 (3.7 × 106–1.2 × 109) | .067 |
Mann-Whitney U test was used for comparing continuous data and group comparisons were made using the Χ2 test. Exact tests were used where applicable.
Abbreviations: ATG, antithymoglobulin; BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein Barr virus; HBc, hepatitis B-core antigen; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; IgG immunoglobulin G; IQR, inter quartile range; NA, not applicable; TTV, torque teno virus.
aTTV levels preceding the first documented event (infection or no infection) per patient were analyzed.
bCutoff defined by median.
cTime between the start of renal replacement therapy and transplantation.
dAny history of major cardiovascular, gastrointestinal, pulmonary, or malignant disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
